Patent ID: 8507545

Claim:
A method for activating cytotoxic T cells in a mammal, comprising administering an effective amount of EP4 agonist selected from the group consisting of 11α,15α,-dihydroxy-9-oxo-16-(3-methoxymethylphenyl)-17,18,19,20-tetranor-3,7-dithiaprost-13E-enoic acid, 4-[(2-{(2R)-2-[(1E,3S)-4-(4-fluorophenyl)-3-hydroxybut-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)sulfanyl]butanoic acid, 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoic acid and methyl 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoate to the mammal.